

## DAFTAR PUSTAKA

- Ajmala, Indana Eva & Wulandari, L. (2015). Terapi ARV pada Penderita Ko-Infeksi TB-HIV. *Jurnal Respirasi*, 1(1), 22–28.
- Anwar, Yelfi; Nugroho, S. A. T. N. D. (2018). Karakteristik Sosiodemografi, Klinis, dan Pola Terapi Antiretroviral Pasien HIV/AIDS di RSPI Dr. Sulianti Saroso Periode Januari-Juni 2016. *Jurnal Farmasi Indonesia*, 15(01), 72–89.
- Aulia.A, Rahayu, Fauzi, P. (2021). Determinan Perubahan Kadar CD4 pada Orang Dengan HIV-AIDS Koinfeksi TB. *Indonesian Journal of Public Health and Nutrition*, 1(1), 472–478. <http://journal.unnes.ac.id/sju/index.php/IJPHN>
- Ayu, I., Wasita, K., Putu, I. W., & Yasa, S. (2017). *Tingkat Kepatuhan Mengonsumsi Obat Antiretroviral dengan Jumlah CD4 pada Pasien HIV AIDS di Klinik VCT RSUP SANGLAH dalam Periode September – November 2014 Program Studi Pendidikan Dokter Bagian Patologi Klinik Fakultas Kedokteran Universitas Udayana Acq.* 6(1), 1–6.
- Bianco, M. da C. A. D., Inacio Leite, D., Silva Castelo Branco, F., Boechat, N., Uliassi, E., Bolognesi, M. L., & Bastos, M. M. (2022). The Use of Zidovudine Pharmacophore in Multi-Target-Directed Ligands for AIDS Therapy. *Molecules*, 27(23). <https://doi.org/10.3390/molecules27238502>
- Bonnet, M., Bhatt, N., Baudin, E., Silva, C., Michon, C., Taburet, A.-M., Laura Ciaffi, A., Sobry, R. B., Nunes, E., Rouzioux, C., Jani, I., & Calmy, A. (2013). Nevirapine versus Efavirenz for Patients Co-Infected with HIV and Tuberculosis: a Randomised Non-Inferiority Trial. *Lancet Infect Dis*, 13, 303–312.
- Claassen, C. W., Keckich, D., Nwizu, C., Abimiku, A., Salami, D., Obiefune, M., Gilliam, B. L., & Amoroso, A. (2019). HIV Viral Dynamics of Lopinavir/Ritonavir Monotherapy as Second-Line Treatment: A Prospective, Single-Arm Trial. *Journal of the International Association of Providers of AIDS Care*, 18, 1–10. <https://doi.org/10.1177/2325958218823209>
- Croxtall, J. D., & Perry, C. M. (2010). *Lopinavir / Ritonavir A Review of its Use in the*

*Management of HIV-I Infection. 70(14), 1885–1915.*

Dewanti, E. & H. (2021). Determinant Viral Load Tersupresi Terhadap Pasien HIV dan AIDS. *Jurnal Mahasiswa BK An-Nur*, 7(3), 60–66.

Dewi, P. A., Hasibuan, P. J., S, W. E., Ilmu, S. M. F., Dalam, P., Santo, R. S., & Pontianak, A. (2019). Keberhasilan terapi Anti Retroviral Lini Pertama ditinjau dari CD4 pada Pasien HIV / AIDS di Klinik Melati RSUD dr . Soedarso Pontianak HIV atau Human Kalimantan Barat merupakan peringkat ke lima dengan rata-rata kasus HIV tertinggi di Indonesia dengan ni. *Jurnal Kesehatan Khatulistiwa*, 5(2A), 747–755.

Dinkes DIY. (2023). *Profil Kesehatan D.I.Yogyakarta Tahun 2022*.

Diress, G., & Linger, M. (2020). Change in Viral Load Count and Its Predictors among Unsuppressed Viral Load Patients Receiving an Enhanced Adherence Counseling Intervention at Three Hospitals in Northern Ethiopia: An exploratory Retrospective Follow-up Study. *HIV/AIDS - Research and Palliative Care*, 12, 869–877. <https://doi.org/10.2147/HIV.S283917>

Evalina, R. (2012). *Studi Deskriptif Infeksi HIV pada Anak di Rumah Sakit Umum Pusat Adam Malik Medan*. 14(2), 73–78.

Harison, N., Waluyo, A., & Jumaiah, W. (2020). Pemahaman pengobatan antiretroviral dan kendala kepatuhan terhadap terapi antiretroviral pasien HIV / AIDS. *Journal Health of Studies*, 4(1), 87–95. <https://doi.org/10.31101/jhes.1008>

Hasanah, U., & Burhannudin. (2023). *Evaluasi Nevirapine pada Terapi ARV Tahun Pertama dan Kedua Terhadap Fungsi Hati di Puskesmas Kecamatan Cilandak : Studi Kadar SGOT dan SGPT*. 03(02), 52–60.

Istiqomah, H., & Suyadi, S. (2019). Perkembangan Fisik Motorik Anak Usia Sekolah Dasar Dalam Proses Pembelajaran (Studi Kasus di SD Muhammadiyah Karangbendo Yogyakarta). *PGMI*, 11(2), 155–168. <https://doi.org/10.20414/elmidad.v11i2.1900>

Kemenkes RI. (2019). Pedoman Nasional Pelayanan Kedokteran Tata Laksana HIV. *Keputusan Menteri Kesehatan Republik Indonesia Nomor*

HK.01.07/MENKES/90/2019, 1–220.

Kemendes RI. (2022a). Optimasi Regimen Obat Antiretroviral Pasien Dewasa dan Anak.

*Surat Edaran Nomor: PM.02.04/C/6007/2022.*

Kemendes RI. (2022b). Penanggulangan HIV, AIDS, dan IMS. *Peraturan Menteri*

*Kesehatan Republik Indonesia No. 831, 1–119.*

Kemendes RI. (2023). *Kasus HIV dan Sifilis Meningkatkan, Penularan Didominasi Ibu Rumah Tangga.*

[https://sehatnegeriku.kemkes.go.id/baca/rilis-media/20230508/5742944/kasus-hiv-dan-sifilis-meningkat-penularan-didominasi-ibu-rumah-tangga/#:~:text=Kasus Human Immunodeficiency Viru \(HIV,yang](https://sehatnegeriku.kemkes.go.id/baca/rilis-media/20230508/5742944/kasus-hiv-dan-sifilis-meningkat-penularan-didominasi-ibu-rumah-tangga/#:~:text=Kasus Human Immunodeficiency Viru (HIV,yang)

terinfeksi HIV mencapai 35%25.

Kumar, P. N., & Patel, P. (2010). Lamivudine for the Teatment of HIV. *Expert Opinion on Drug Metabolism and Toxicology*, 6(1), 105–114.

<https://doi.org/10.1517/17425250903490418>

Kurniawati, V. V., Harioputro, D. R., & Susanto, A. J. (2022). Evaluasi Kadar Sel Cd4, Viral Load, Dan Neutrophil Lymphocyte Ratio (Nlr) Terhadap Infeksi Oportunistik Pada Pasien Hiv/Aids. *Biomedika*, 14(2), 99–107.

<https://doi.org/10.23917/biomedika.v14i2.17299>

Liansyah, T. M. (2018). Aspek Klinis dan Tatalaksana Bayi dengan Ibu Penderita HIV/AIDS. *Jurnal Kedokteran Nanggroe Medika*, 1(4), 32–38.

<http://www.jknamed.com/jknamed/article/view/32>

Mdanda, S., Ntshangase, S., Singh, S. D., Naicker, T., Kruger, H. G., Baijnath, S., & Govender, T. (2019). Zidovudine and Lamivudine as Potential Agents to Combat HIV-Associated Neurocognitive Disorder. *Assay and Drug Development Technologies*, 17(7), 322–329. <https://doi.org/10.1089/adt.2019.941>

*Technologies*, 17(7), 322–329. <https://doi.org/10.1089/adt.2019.941>

Pangarungan, M. (2017). Faktor Prognostik Gagal Terapi Virologi pada Pasien HIV Anak dalam Terapi Antiretroviral Lini Pertama di RSUP Dr. Sardjito Yogyakarta. *Tesis, Kedokteran.*

Shearer, K., Brennan, A. T., Maskew, M., Long, L., Berhanu, R., Sanne, I., & Fox, M. P. (2014). The Relation Between Efavirenz versus Nevirapine and Virologic Failure in

- Johannesburg, South Africa. *Journal of the International AIDS Society*, 17, 1–10.  
<https://doi.org/10.7448/IAS.17.1.19065>
- Sinha, S., Raghunandan, P., Chandrashekhar, R., Sharma, S. K., Kumar, S., Dhooria, S., Ekka, M., Velpandian, T., Ranjan, S., Ahmad, H., Samantaray, J. C., Venkatesh, S., Rewari, B. B., Khan, N. H., & Pandey, R. M. (2013). Nevirapine versus Efavirenz-Based Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients with HIV and Tuberculosis Infections in India: a Pilot Study. *BMC Infectious Diseases*, 13(483), 1–9.
- Ssebutinde, P., Kyamwanga, I. T., Turyakira, E., Asiimwe, S., & Bajunirwe, F. (2018). Effect of Age at Initiation of Antiretroviral Therapy on Treatment Outcomes; A Retrospective Cohort Study at a Large HIV Clinic in Southwestern Uganda. *PLoS ONE*, 13(8), 1–14. <https://doi.org/10.1371/journal.pone.0201898>
- Syawaludin, M., & Muhimmah, I. (2021). Desain Prototipe Sistem Monitoring Minum Obat Bagi Odha. *JIKO (Jurnal Informatika Dan Komputer)*, 4(2), 76–85. <https://doi.org/10.33387/jiko.v4i2.2226>
- Team, W. technical. (2023). *People living with HIV People acquiring HIV People dying from HIV-related causes*. 1–3.
- van Leth, F., Phanuphak, P., Ruxrungtham, K., Baraldi, E., Miller, S., Gazzard, B., Cahn, P., Lalloo, U. G., van der Westhuizen, I. P., Malan, D. R., Johnson, M. A., Santos, B. R., Mulcahy, F., Wood, R., Levi, G. C., Reboredo, G., Squires, K., Cassetti, I., Petit, D., ... Lange, J. M. A. (2004). Comparison of First-Line Antiretroviral Therapy with Regimens Including Nevirapine, Efavirenz, or Both Drugs, plus Stavudine and Lamivudine: a Randomised Open-Label Trial, the 2NN Study. *The Lancet*, 363(9417), 1253–1263.  
[http://www.researchgate.net/profile/Frank\\_Leth/publication/8609969\\_Van\\_Leth\\_F\\_Phanuphak\\_P\\_Ruxrungtham\\_K\\_Baraldi\\_E\\_Miller\\_S\\_Gazzard\\_B\\_et\\_al\\_Comparison\\_of\\_first-line\\_antiretroviral\\_therapy\\_with\\_regimens\\_including\\_nevirapine\\_efavirenz\\_or\\_both\\_drugs\\_plus\\_stavudine\\_and\\_lamivudine\\_a\\_randomised\\_open\\_label\\_trial\\_the\\_2nn\\_study](http://www.researchgate.net/profile/Frank_Leth/publication/8609969_Van_Leth_F_Phanuphak_P_Ruxrungtham_K_Baraldi_E_Miller_S_Gazzard_B_et_al_Comparison_of_first-line_antiretroviral_therapy_with_regimens_including_nevirapine_efavirenz_or_both_drugs_plus_stavudine_and_lamivudine_a_randomised_open_label_trial_the_2nn_study)

WHO. (2023). *HIV*. <https://www.who.int/data/gho/data/themes/hiv-aids>

Yogani, I. T. H. K., Uyainah, A., & Koesnoe, S. (2015). Faktor-Faktor Yang Berhubungan Dengan Kenaikan CD4 Pada Pasien HIV Yang Mendapat Highly Active Antiretroviral Therapy Dalam 6 Bulan Pertama. *Jurnal Penyakit Dalam Indonesia*, 2(4).

Yuliandra, Y., Nosa, U.S., Raveinal, & Almasdy, D. (2017). Terapi Antiretroviral pada Pasien HIV / AIDS di RSUP . Dr . M . *Jurnal Sains Farmasi & Klinis*, 04(01), 1–8. <https://doi.org/10.29208/jsfk.2017.4.1.173>

Yuliyanasari, N. (2017). Global Burden Disease – Human Immunodeficiency Virus – Acquired Immune Deficiency Syndrome ( Hiv-Aids ). *Qanun*, 01(October 2016), 65–77. <http://journal.um-surabaya.ac.id/index.php/qanunmedika/article/download/385/294>